02:50 PM EDT, 04/29/2024 (MT Newswires) -- Immix Biopharma ( IMMX ) said Monday that the European Commission has granted orphan drug designation to NXC-201 for the treatment of multiple myeloma.

The designation qualifies NXC-201 among others for 10 years of market exclusivity once authorized in the EU and access to the EU centralized authorization procedure, the company said.

The shares were down more than 4% in recent trading.

Price: 2.03, Change: -0.10, Percent Change: -4.69